The U.S. Patent and Trademarks Office granted Immuron a patent for its non-alcoholic steatohepatitis treatment.
Here's what you should know:
1. The office approved Immuron's "Anti-LPS Enriched Immunoglobulin for Use in treatment and/or Prophylaxis of a Pathological Disorder" patent.
2. The patent is comprised of 10 allowed claims. It covers Immuron's method for treating NASH with a colostrum-based composition.
3. Bristol-Myers Squibb and Pfizer each recently increased efforts to "bolster product development in the sector," according to Immuron's release.
Immuron's Interim CEO Jerry Kanellos said, "This new patent is a key milestone for Immuron as it further establishes the intellectual property position of our NASH program in the U.S. and complements the patents already granted in Australia. We believe this success paves the way for patent grants in other key jurisdictions, strengthening Immuron's presence in the global NASH treatment market."